Table 2.

Clinical trials in vaccines targeting EBV-associated antigens (non-exhaustive list).

Identifier and Reference	Vaccine ± Other Therapy	Phase	Type of Vaccine	N	Target Antigens	Population	Primary Endpoint	Status
NCT01147991 Ref. [84]	MVA-EL	I	Live (MVA virus)	16	EBNA1 LMP2	EBV-induced NPC in CR after first-line treatment	Safety and IR	Completed
NCT01256853 Ref. [87]	MVA-EL	I	Live (MVA virus)	18	EBNA1 LMP2	EBV-induced NPC in CR or unconfirmed CR	Safety	Completed
NCT01800071 NA	MVA-EBNA1/LMP2	Ib	Live (MVA virus)	22	EBNA1 LMP2	EBV-induced NPC in remission or with current disease for whom no standard therapy is currently appropriate or required	IR and Safety	Completed
NCT01094405 NA	MVA EBNA1/LMP2 vaccine	II	Live (MVA virus)	25	EBNA1 LMP2	Persistent, recurrent, or metastatic NPC that have residual EBV DNA following completion of conventional therapy	Efficacy	Completed
NA Ref. [85]	DC vaccine	I	Autologous DCs	16	LMP2	Local recurrence or metastasis NPC	Safety	Completed
NA Ref. [86]	DC vaccine	?	Autologous DCs	16	LMP2	Stage II-III NPC	IR	Completed
NA Ref. [88]	Ad-ΔLMP1-LMP2 DC vaccine	II	Autologous DCs transducted with an adenovirus	16	LMP1 LMP2	Refractory metastatic NPC	Efficacy	NA
NCT00078494 NA	LMP-2:340–349 or LMP-2:419–427	I/II	Peptide	99	LMP2	Locally controlled anaplastic NPC	IR	Completed
NCT00589186 NA	Ad5F35-LMP1/LMP2-transduced autologous DCs + Celecoxib	II	Autologous DCs transducted with an adenovirus	±35	LMP1 LMP2	Metastatic NPC	Efficacy	Unknown

CR: complete response; DC: dendritic cell; EBV: Epstein–Barr virus; IL: interleukin; IR: immune response; MVA: modified vaccinia Ankara; NA: not available; NPC: nasopharyngeal carcinoma.